• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

CVRx touts positive two-year data for heart failure neuromodulation device

cafead

Administrator
Staff member
  • cafead   Sep 12, 2024 at 07:32: PM
via Building on long-term data announced earlier this year, CVRx has reported durable improvements in heart failure patients with its Barostim device over 24 months.

The results, published in the Journal of the American College of Cardiology: Heart Failure, demonstrated that patients implanted with the Barostim reported feeling significantly better in a variety of physical and psychosocial measures.

article source
 

<